Hepatocellular Carcinoma Recurrence Risk in the Context of Emerging Therapies
- PMID: 35513591
- DOI: 10.1245/s10434-022-11709-8
Hepatocellular Carcinoma Recurrence Risk in the Context of Emerging Therapies
References
-
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. - DOI
-
- Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol. 2013;10(11):656–565. - DOI
-
- Shiels MS, O’Brien TR. Recent decline in hepatocellular carcinoma rates in the United States. Gastroenterology. 2020;158(5):1503-1505.e2. - DOI
-
- Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol. 2003;38(3):207–15. - DOI
-
- Adhoute X, Penaranda G, Raoul JL, et al. Usefulness of staging systems and prognostic scores for hepatocellular carcinoma treatments. World J Hepatol. 2016;8(17):703–15. - DOI
Publication types
LinkOut - more resources
Full Text Sources
